Authorized health care providers should now order the monoclonal antibody therapy bamlanivimab and antibody cocktail casirivimab/imdevimab directly from the sole distributor, AmerisourceBergen Corp., the Department of Health and Human Services announced Friday.

HHS’ Office of the Assistant Secretary for Preparedness and Response will no longer allocate the therapies to health departments because the drugs are no longer in short supply, the agency said, noting that the products remain free of charge to requesting sites. “HHS will continue to monitor all direct orders, and we retain the capacity to resume allocation of these and future therapies if needed.” For more on the direct ordering process, see the ASPR guide.

The Food and Drug Administration in November issued emergency use authorizations for bamlanivimab and casirivimab/imdevimab to treat certain COVID-19 outpatients at risk for severe disease.

Related News Articles

Headline
President Biden yesterday continued the national emergency for the COVID-19 pandemic beyond March 1. The renewed national emergency, along with the recently…
Headline
The AHA and eight other hospital organizations today urged Senate leaders to include additional COVID-19 relief funding for health care providers in the…
Headline
The Food and Drug Administration's Office of Minority Health and Health Equity today released two videos on COVID-19 vaccines and the importance of communities…
Headline
The AHA has received $6 million in grants from the Centers for Disease Control and Prevention to promote clinician and public confidence in COVID-19 vaccines,…
Headline
Data submitted to the Food and Drug Administration confirms that Johnson & Johnson’s COVID-19 vaccine candidate is safe and effective. According to the…
Headline
President Biden today will sign an executive order to create more resilient and secure supply chains for critical and essential goods, the White House…